The Effect of MK0633 in Patients With Chronic Asthma (0633-007)

Phase 2TerminatedNCT00404313

Merck Sharp & Dohme LLC688 enrolled

Overview

A clinical study to evaluate the efficacy and safety of MK0633 in adult patients with chronic asthma.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

688

Conditions

Asthma

Interventions

MK0633DRUG

Patients will receive 10 mg, 50 mg, or 100 mg MK0633 tablets once daily for 6 weeks. There will be 2 week period during which all patients will receive placebo to MK0633

Comparator: placeboDRUG

Placebo to MK0633 10 mg, 50 mg, or 100 mg tablets once daily for 6 weeks

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Documented clinical history of symptoms of chronic asthma, including dyspnea, wheezing, chest tightness, cough, and/or sputum production * Males and females 18-70 years of age Exclusion Criteria: * History of kidney or chronic liver disease * Recent history of heart problems within the past 3 months * Evidence of another clinically significant, active lung disorder such as bronchiectasis or COPD

Outcomes

Primary Outcomes

Pulmonary function test data measured over 6 weeks

Time frame: 6 weeks

Secondary Outcomes

Overall daytime and nighttime symptoms score, beta-agonist use, asthma exacerbations, asthma-specific quality of life questionnaire score, measured over 6 weeks

Time frame: 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.